Previous close | 32.10 |
Open | 32.10 |
Bid | 35.40 |
Ask | 36.00 |
Strike | 20.00 |
Expiry date | 2025-01-17 |
Day's range | 32.10 - 32.10 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as "most serious". An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding, the agency said. Bowel ischemia describes disorders that occur when blood flow to your intestines decrease, causing severe abdominal pain.
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.